Circulating tumor DNA analysis in patients with EGFR mutant lung cancer

Genotype-oriented treatment has led to dramatic clinical improvements for patients with non-small cell lung cancer (NSCLC) harboring a targetable oncogenic driver (1). The identification of several targetable oncogenes and improved knowledge of resistance mechanisms provide rationale for obtaining clinical samples to assess tumor biology and the evolution of drug resistance (2).